Researchers: Mesothelioma Trials Need More Inclusive Criteria

Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney, Australia. The study demonstrated a significant difference between those carefully selected for clinical trials and real-world patients with pleural mesothelioma. “A broader patient population more resembling real life would be able to access the novel treatment early,” Dr. Steven Kao, medical oncologist at Chris O’Brien Lifehouse hospital and one of the study authors, told The Mesothelioma Center at Asbestos.com. “And when the trial results are published, the efficacy results would be more applicable to the real-world population.” Clinical Lung Cancer published the study in 2020, accentuating the high rates of ineligibility caused by criteria that is too strict, potentially denying many patients the chance for improved mesothelioma survival. Authors were from the University of Sydney Medical School and the Chris O’Brien Lifehouse Department of Medical Oncology. The retrospective study ran from 2012 to 2018 and involved 133 consecutive patients with unresectable malignant pleural mesothelioma. All attended the medical oncology clinic at Royal Prince Alfred or Chris O’Brien Lifehouse hospitals in Sydney. Qualifying for Mesothelioma Clinical Trials Is Difficult Data for the study was compared to eligibility criteria for the international MAPS and KEYNOTE-028 studies, involving ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news